Showing results (401-410 of 6,286) with videos related to

Sort By:
Pageof 629
Diabetes, Obesity & Metabolism|October 21, 2016
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trialsFrancisco J Tinahones, Baptist Gallwitz, Matias Nordaby, et al.
Diabetes, Obesity & Metabolism|November 22, 2016
Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group studyChristian S Frandsen, Thomas F Dejgaard, Henrik U Andersen, et al.
Diabetes, Obesity & Metabolism|November 25, 2016
Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort studyLotte M Knapen, Roy G P J de Jong, Johanna H M Driessen, et al.
Diabetes, Obesity & Metabolism|November 27, 2016
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetesNiels Porksen, Helle Linnebjerg, Parag Garhyan, et al.
Diabetes, Obesity & Metabolism|December 13, 2016
Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort studyJohanna H M Driessen, Joop P W van den Bergh, Hein A W van Onzenoort, et al.
Diabetes, Obesity & Metabolism|December 10, 2016
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trialJohn R Petrie, Nish Chaturvedi, Ian Ford, et al.
Diabetes, Obesity & Metabolism|December 10, 2016
Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetesThomas F Dejgaard, Nanna B Johansen, Christian S Frandsen, et al.
Diabetes, Obesity & Metabolism|December 18, 2016
Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetesChristoph Kapitza, Irene Nowotny, Anne Lehmann, et al.
Diabetes, Obesity & Metabolism|December 27, 2016
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathyMichelle J Pena, Dick de Zeeuw, Dennis Andress, et al.
Diabetes, Obesity & Metabolism|December 16, 2016
Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusionAmparo de la Peña, Corina Loghin, Xuewei Cui, et al.
Pageof 629